Outcomes of primary rotator cuff repair in non-diabetic patients using glucagon-like peptide-1 (GLP-1) receptor agonists: A propensity-matched analysis

使用胰高血糖素样肽-1 (GLP-1) 受体激动剂治疗非糖尿病患者初次肩袖修复的疗效:倾向性匹配分析

阅读:1

Abstract

INTRODUCTION: Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has surged among non-diabetic individuals in response to the obesity epidemic. Their influence on musculoskeletal healing and orthopedic surgical outcomes remains poorly characterized. The purpose of this study is to evaluate postoperative outcomes following primary rotator cuff repair (RCR) in non-diabetic patients treated with GLP-1 RA. METHODS: A retrospective cohort study was conducted using the TriNetX database to identify non-diabetic patients who underwent RCR. Patients prescribed GLP-1 RA were propensity score-matched 1:1 with non-users based on demographics and comorbidities. Surgical and medical outcomes were compared using risk ratios (RRs) with 95% confidence intervals. RESULTS: GLP-1 RA use was associated with significantly lower rates of re-tear (RR = 0.699, p < 0.001) and occupational therapy utilization (RR = 0.686, p < 0.011). There were no significant differences in readmission rates, emergency department utilization, or mortality between groups. However, GLP-1 RA users had higher rates of cardiovascular complications (RR = 1.426, p = 0.038). CONCLUSION: GLP-1 RA use was associated with reduced rates of re-tear and occupational therapy utilization. No differences were observed in readmission rates, emergency department utilization, or mortality. These findings suggest a potential benefit of GLP-1 RA in musculoskeletal healing, though further investigation is needed to understand the mechanisms involved.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。